ASH: As Novartis enters PNH market, AstraZeneca shows longer term effect of its latest contender

The week after Novartis secured a foothold in the paroxysmal nocturnal hemoglobinuria (PNH) market, AstraZeneca has released new data from its own attempt to find fresh ways of tackling this rare blood disease.